Assessment of pazopanib-related hypertension, cardiac dysfunction and identification of clinical risk factors for their development.

Cardiooncology · 2017 · PMC5828231 · PMID 29497565

Europe PMC DOI

hedged sentence

0.0440

closest p · 0.9× alpha

0.0440

boldest claim

The sentences

a strong trendp = 0.044actually significant

ACEi/ARBs (46%) and CCBs (27%) accounted for the majority of these (Table 3 ). Baseline SBP ≥ 130 mmHg (OR: 5.32; 95% CI: 0.94-29.99; p = 0.058) had a strong trend towards significance as a univariate predictor of development of HTN, and treatment with an ACEi or ARB (OR: 4.88; 95% CI: 1.05-22.84; p = 0.044) was a significant univariate predictor of development of pazopanib-induced HTN (Table 4 ).

also in 5,725 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.